Downstream Processing: A Revalidation Study of Viral Clearance in the Purification of Monoclonal Antibody CB.Hep-1 - - BioPharm International

ADVERTISEMENT

Downstream Processing: A Revalidation Study of Viral Clearance in the Purification of Monoclonal Antibody CB.Hep-1

ABSTRACT

This article revalidates the effectiveness of affinity chromatography, matrix sanitization, and storage procedures used in monoclonal antibody CB.Hep-1 purification to remove and inactivate viruses after process scale-up. The scale up of the CB.Hep-1 purification process demonstrated a similar removal factor for enveloped and nonenveloped viruses compared to the initial validation study. The HSV-1, HIV-1, and CPV viruses were sensitive to incubation with ethanol at 70% concentration (3.0–4.6 Logs). We found that 0.1N HCl is a robust chemical agent able to inactivate >6.13 Logs of nonenveloped high resistance viruses while ethanol at 20% concentration inactivated 3.7 Logs of enveloped viruses HSV-1 and HIV-1 but was unable to inactivate nonenveloped viruses HPV-1 and CPV.



Monoclonal antibodies (MAbs) are employed as immunoligands in the purification processes of biopharmaceutical products.1,2 Virus transmission poses a high potential risk for patients who must be treated with these biopharmaceuticals, if MAbs come from human or animal sources.3,4 It is necessary to validate the purification process capacity to remove and inactivate any potential viral contaminant.5,6

Regardless of extreme virus controls, several instances of biological contamination have occurred. Research on virus contamination sources have shown that viruses can be introduced into the manufacturing process in different ways, illustrating the importance of viral clearance studies to guarantee the biopharmaceutical product safety.7


Acronym List
Validation of the purification method plays an essential role in establishing biological product safety, especially when there is a high risk for the source to be contaminated with known human pathogenic viruses. Since several contamination instances have occurred with agents whose presence was not known, validation also provides a high degree of confidence that these agents may also be removed.8

FDA defines validation as, "Establishing documented evidence, which provides a high degree of assurance that a specific process will consistently produce a product meeting its pre-determined specifications and quality attributes".9 The rationale is that if more effort is placed on validation at the beginning, then there will be less chance for failure during product life.10

Validation studies for purifications proceses involve the deliberate addition of a virus to one or more purification steps to measure the extent of its removal and inactivation capacity. It is not necessary to validate all purification steps, but only those that could contribute to virus removal or inactivation. To prevent the deliberate introduction of viruses into the manufacturing process, the validation studies should be done in a separate facility and in a scaled-down version of the manufacturing process. Validation at the small scale is an efficient way to perform viral clearance validation studies.11

GENERAL PROCEDURE FOR VALIDATION

CB.Hep-1 MAb is a mouse IgG-2b, specific for HbsAg.12 This MAb is used as an immunoligand in the antigen-purification process, which is one step in the manufacturing of the Hepatitis B vaccine for human use.13,14 The main aim of our work was to investigate if the affinity chromatography used routinely in the purification of CB.Hep-1 shows the same virus removal factor after a scale-up process. We measured the virus inactivation factor of the column sanitization protocol using 70% ethanol and the matrix storage conditions in 20% ethanol. We also evaluated the column sanitization protocol with 0.1 N HCl to increase the inactivation factor for high resistance non-enveloped viruses.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

New Tax Rules May Deter Future Pharma M&A
October 1, 2014
NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
New Report Details Players and Pipelines in the Biosimilar Space
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
Author Guidelines
Source: BioPharm International,
Click here